Overview

An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone

Status:
Completed

Trial end date:
2006-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the maintenance of clinical effect of a rapidly-dissolving tablet form of risperidone (an antipsychotic medication) in adult schizophrenia patients switched from their previous equivalent dose of RISPERDAL® tablets

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Ortho Inc., Canada

Treatments:

Risperidone